Search | Clinical Trials Finder

Conditions: Delayed Graft Function
Interventions: Eculizumab, Placebo; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 288 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 32
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 27 more

Conditions: Tetralogy of Fallot
Interventions: Cardiac Magnetic Resonance Imaging (CMRI), Central venous line placement, Chest X-ray, Fluid administration, Blood Draw, Pregnancy test, Electrocardiogram; Procedure
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Cervical Radiculopathy
Interventions: cervical interlaminar with lidocaine, cervical interlaminar with normal saline, Lidocaine, Triamcinolone Acetonide, Normal saline; Procedure · Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years to 80 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Influenza, Swine-origin A/H1N1 Influenza
Interventions: Monovalent Subvirion A/H1N1 Influenza vaccine (7.5 µg of HA), Monovalent Subvirion A/H1N1 Influenza vaccine (15 µg of HA), Monovalent Subvirion A/H1N1 Influenza vaccine (30 µg of HA), Normal saline solution (placebo); Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 18 Years and older
Enrollment: 849 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 15
States / cities: Hoover, Alabama • Chandler, Arizona • Phoenix, Arizona + 12 more

Conditions: Influenza
Interventions: GSK Biologicals' FluLaval®, Placebo (saline), GSK Biologicals' investigational H1N1 Influenza Vaccine - GSK2340274A, GSK Biologicals' investigational H1N1 Influenza Vaccine - GSK2340273A; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 19 Years to 40 Years
Enrollment: 133 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 3
States / cities: Milford, Massachusetts • Salisbury, North Carolina • Winston-Salem, North Carolina

Conditions: Chronic Kidney Diseases
Interventions: Visipaque, Placebos; Drug
Lead sponsor: GE Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 17
States / cities: Birmingham, Alabama • Mesa, Arizona • Little Rock, Arkansas + 14 more

Conditions: Healthy, HIV
Interventions: Tenofovir disoproxil fumarate intravaginal ring, Placebo intravaginal ring (IVR); Drug
Lead sponsor: Marla Keller; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: HIV Infections
Interventions: AIDSVAX B/E Vaccine, DNA-HIV-PT123 Vaccine, Placebo for DNA-HIV-PT123, Placebo for AIDSVAX B/E; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 104 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 7
States / cities: San Francisco, California • New York, New York • Rochester, New York + 3 more

Conditions: Group B Streptococcus Infections
Interventions: Multivalent Group B streptococcus vaccine, Tetanus, diphtheria, and acellular pertussis vaccine, Placebo; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 49 Years · Female only
Enrollment: 306 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 12
States / cities: Newton, Kansas • Omaha, Nebraska • Las Vegas, Nevada + 8 more

Conditions: Cocaine Use Disorder
Interventions: STP7 (mavoglurant), Placebo, Cocaine Hydrochloride; Drug
Lead sponsor: Stalicla SA; Industry
Eligibility: 18 Years to 59 Years
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Influenza
Interventions: AS03 Adjuvant, Phosphate Buffered Saline (PBS) diluent, Sanofi H5N1 Antigen; Drug · Other · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 49 Years
Enrollment: 245 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 4
States / cities: Baltimore, Maryland • Nashville, Tennessee • Houston, Texas + 1 more

Conditions: Skin Quality
Interventions: Hyper-Diluted Botox, Topical anesthesia, 0.9% saline solution; Drug · Other
Lead sponsor: Steve Yoelin M.D. Medical Associates, Inc.; Other
Eligibility: 35 Years to 55 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Newport Beach, California

Conditions: Blunt Trauma, Penetrating Wound, Hemorrhagic Shock
Interventions: 0.9% Sodium Chloride 250 mL bolus, 0.9% Sodium Chloride 2000 mL bolus; Drug
Lead sponsor: University of Washington; Other
Eligibility: 15 Years and older
Enrollment: 192 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 5
States / cities: Birmingham, Alabama • Portland, Oregon • Pittsburgh, Pennsylvania + 2 more

Conditions: Moderate to Severe Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines, and Lateral Canthal Lines)
Interventions: NT 201, Placebo; Drug
Lead sponsor: Merz North America, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 362 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 12
States / cities: Encino, California • Newport Beach, California • San Diego, California + 7 more

Conditions: Cleft Palate Children
Interventions: Ultrasound-guided bilateral suprazygomatic maxillary nerve block, Local anesthetic infiltration of the palate; Procedure
Lead sponsor: Ann & Robert H Lurie Children's Hospital of Chicago; Other
Eligibility: 9 Months to 2 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Laparoscopic Adnexal Surgery
Interventions: Normal Saline (0.9% NaCl), Marcaine hydrochloride without epinephrine 0.5%; Other · Drug
Lead sponsor: University of Tennessee; Other
Eligibility: 18 Years and older · Female only
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Gastro Intestinal Bleeding, Upper Gastrointestinal Bleeding
Interventions: Azithromycin Injection, Metoclopramide Injectable Solution, Sodium chloride 0.9%; Drug
Lead sponsor: Waihong Chung; Other
Eligibility: 18 Years and older
Enrollment: 435 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Contrast Medium-induced Nephropathy
Interventions: LVEDP -Based hydration strategy, Standard hydration; Other
Lead sponsor: Kaiser Permanente; Other
Eligibility: 18 Years and older
Enrollment: 396 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Osteoarthritis of the Knee
Interventions: FX006 32 mg, Placebo, FX006 16 mg; Drug
Lead sponsor: Pacira Pharmaceuticals, Inc; Industry
Eligibility: 40 Years and older
Enrollment: 310 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 39
States / cities: Anniston, Alabama • Birmingham, Alabama • Mobile, Alabama + 36 more

Conditions: Osteoarthritis
Interventions: Bone Marrow Derived MSCs, Adipose-derived MSCs, Umbilical Cord Tissue (UCT) MSCs, Corticosteroid injection; Biological · Drug
Lead sponsor: Emory University; Other
Eligibility: 40 Years to 70 Years
Enrollment: 475 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 5
States / cities: Gulf Breeze, Florida • Atlanta, Georgia • Durham, North Carolina + 2 more

Conditions: Critical Limb Ischemia
Interventions: Low Dose VM202, High Dose VM202, Placebo; Biological · Other
Lead sponsor: Helixmith Co., Ltd.; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2023
U.S. locations: 13
States / cities: Birmingham, Alabama • Orange, California • Chicago, Illinois + 9 more

Conditions: Healthy
Interventions: MVA-BN-Filo, Ad26. ZEBOV, Placebo; Biological · Other
Lead sponsor: Janssen Vaccines & Prevention B.V.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 164 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Rockville, Maryland

Conditions: Cervical Dystonia
Interventions: DaxibotulinumtoxinA for injection, Placebo; Biological
Lead sponsor: Revance Therapeutics, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 301 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 44
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Fountain Valley, California + 38 more

Conditions: Extreme Prematurity, Intraventricular Hemorrhage, Morbidity;Newborn
Interventions: Indomethacin, Placebo; Drug
Lead sponsor: University of British Columbia; Other
Eligibility: 0 Hours to 12 Hours
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 5
States / cities: Roseville, California • Sacramento, California • Pittsburgh, Pennsylvania + 1 more

Search by objective public record fields.

Prevention of Delayed Graft Function Using Eculizumab Therapy (PROTECT Study)

Effects of Changes in Fluid Status on Right Ventricular Volumes and Function

Does Low-does Cervical Epidural Lidocaine Cause Transient Weakness?

A Study of Different Formulations of an A/H1N1 Pandemic Vaccine in Healthy Adults and the Elderly

Safety and Immune Response of Candidate H1N1 Influenza Vaccine GSK2340274A Following Seasonal Influenza Vaccination in Adults

A Study to Explore the Renal Safety of Visipaque Injection 320 mgI/mL in Patients With Chronic Kidney Disease

Safety and Pharmacokinetics (PK) of a Polyurethane Tenofovir Disoproxil Fumarate (TDF) Vaginal Ring (TDF IVR-002)

Evaluating the Safety and Immune Response to Different Combinations of the DNA-HIV-PT123 and AIDSVAX® B/E Vaccines in Healthy, HIV-Uninfected Adults

Trial to Evaluate the Safety, Tolerability, and Immunogenicity of A Multivalent Group B Streptococcus Vaccine When Administered Concomitantly With Tdap in Healthy Nonpregnant Women

Phase1, STP7 Cocaine Drug-Drug Interaction Study

H5N1 Mix and Match With AS03

Evaluation of Skin Quality Improvement

Field Trial of Hypotensive Versus Standard Resuscitation for Hemorrhagic Shock After Trauma

Safety and Efficacy Study of the Simultaneous Treatment of Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines and Lateral Canthal Lines) in Subjects With Moderate to Severe Upper Facial Lines

Suprazygomatic Maxillary Nerve Block in Cleft Palate Outcomes

Pain with Differing Intraperitoneal Washes At the End of Laparoscopic Gynecologic Surgery

Metoclopramide, Azithromycin, or Nondrug Pretreatment for UGIB to Reduce Second Endoscopy

Prevention of Contrast Renal Injury With Different Hydration Strategies

Study of FX006 vs Normal Saline in Patients With Osteoarthritis of the Knee

Multicenter Trial of Stem Cell Therapy for Osteoarthritis (MILES)

Safety and Efficacy Study Using Gene Therapy for Critical Limb Ischemia

A Safety and Immunogenicity Study of Heterologous and Homologous Prime-Boost Ebola Vaccine Regimens in Healthy Participants

Single Treatment of DaxibotulinumtoxinA for Injection in Adults With Isolated Cervical Dystonia (ASPEN-1)

Single-dose Prophylactic INdomethacin in Extremely Preterm Infants